

**ROSWELL PARK CANCER INSTITUTE CORPORATION
TECHNOLOGY TRANSFER COMMITTEE
OF THE BOARD OF DIRECTORS**

A meeting of the Technology Transfer Committee of the Board of Directors of Roswell Park Cancer Institute Corporation was held on Thursday April 18, 2018 at 8:30 a.m. in the Patrick Lee Conference Room, 9th Floor, Scott Bieler Clinical Services Center of the Institute.

Present: Nora. B. Sullivan – Chairperson
June W. Hoeflich
Kenneth Manning
Noah Rifkin
Candace S. Johnson, PhD, President & Chief Executive Officer

Excused: Michael L. Joseph, Chairman of the Board
Joseph Dunn, PhD

**Present by
Invitation:** Michael B. Sexton, Esq., Chief Administrative Officer and General
Counsel – Secretary
Gregory McDonald, Chief Financial Officer
Patrick Emmerling, PhD, Interim Director of the Technology Transfer Office
Kristen Castner, Intellectual Property Manager
Camille Wicher, Ph.D., Esq. MSN, RN, Vice President
Douglas Plessinger, Chief Clinical & Scientific Development Officer – Global
Biotech & Cancer Therapeutics
Betsy Doty-Lampson, Administrator to the Board of Directors
Ericka N. Bennett, Esq., Associate General Counsel

Ms. Sullivan opened the meeting and thanked all for attending the meeting, and acknowledged Harl Tolbert's departure to accept a position at Penn State University. Ms. Sullivan stated that Patrick Emmerling is serving as Interim Director of the Technology Transfer Office. Ms. Sullivan thanked Michael Sexton and the members of the Technology Transfer Office for keeping things going during the transition. Ms. Sullivan also thanked Ms. Doty-Lampson for her assistance with the board materials.

Ms. Sullivan asked for a motion to approve the November meeting minutes which was made by Mr. Manning and seconded by Mr. Rifkin. The motion was unanimously approved.

Ms. Sullivan discussed the Technology Transfer Committee Charter. Mr. Sexton clarified that the Committee composition of four members of the board of directors and three community members needed to be changed to reflect what was decided by the Board of Directors.

Mr. Emmerling provided an update on Empire Genomics, LLC ("Empire Genomics"), noting that Roswell Park has not received royalty payments from Empire Genomics in two (2) years. Mr. Emmerling stated that the last payment was received in 2017 and that payment was for FY 2015 and 2016. He stated that he is looking forward to seeing the royalty reports from Empire Genomics. There was a discussion of whether a breach notice should be sent to Empire Genomics. Ms. Sullivan stated that Mr. Sexton will reach out to Empire Genomics, and if that doesn't work, Dr. Johnson will reach out to Empire Genomics.

Mr. Plessinger presented information on the Empire Discovery Institute ("EDI"), a New York State supported initiative between Roswell Park, the State University of New York at Buffalo and the University of Rochester. Mr. Plessinger stated that the goal of EDI is to help researchers facilitate their research. The program will compliment what is done here, Mr. Plessinger stated. He stated that EDI has hired Judy Dunn, PhD as its executive director. Mr. Plessinger stated that initially there may be 5-8 projects undertaken by EDI. The initial thoughts of leadership are that that they would fund the projects annually for 3-5 years, Mr. Plessinger stated. The home institution and faculty will retain ownership of inventions. Committee members discussed the possible role of the Committee in Roswell Park EDI submissions. There was a discussion of what the Committee's role may be in recommending projects for consideration by EDI. Mr. Emmerling stated that EDI will help to advance technologies that would otherwise stall out.

Mr. Emmerling provided a financial update on the Technology Transfer Office.

Ms. Sullivan asked for a motion to adjourn the meeting which was made by Mr. Manning and seconded by Ms. Hoeflich. The motion was unanimously approved.

There being no further business, the meeting was duly adjourned.

The Committee members were invited to remain after the meeting to discuss the search for a Director of the Technology Transfer Office.

Respectfully submitted,


Michael B. Sexton, Esq.